Hengeler Mueller advises UCB on sale of its internal medicine unit
31. July 2018
Hengeler Mueller has advised UCB Pharma GmbH, part of the Belgian UCB Group, on the sale of its internal medicine unit to private equity investor Paragon Partners. Internal medicine, which has been operating as a separate business entity since March 2016, has been successfully promoting pharmaceutical products in Germany for many years, mainly for cardiovascular and respiratory diseases.
Hengeler Mueller has advised UCB on the carve out of the internal medicine unit and the subsequent sales auction process. The Hengeler Mueller team included partners Carsten Schapmann (Corporate/M&A), Martin Ulbrich (M&A) (both Düsseldorf), Martin Klein (Tax), Hendrik Bockenheimer (Labour) (both Frankfurt), Alf-Henrik Bischke (Antitrust, Düsseldorf), counsel Patrick H. Wilkening (IP, Düsseldorf) and Matthias Berberich (IP, Berlin) as well as associates Gianna Velte, Tobias Schneiders, Richard Suermann (all Corporate/M&A, Düsseldorf), Sebastian Heinrichs (Tax), Eckbert Müller (Labour) (both Frankfurt) and Tobias Bieber (Antitrust, Düsseldorf).